134 related articles for article (PubMed ID: 27651368)
1. Pim kinase isoforms: devils defending cancer cells from therapeutic and immune attacks.
Jinesh GG; Mokkapati S; Zhu K; Morales EE
Apoptosis; 2016 Nov; 21(11):1203-1213. PubMed ID: 27651368
[TBL] [Abstract][Full Text] [Related]
2. PIM kinase (and Akt) biology and signaling in tumors.
Warfel NA; Kraft AS
Pharmacol Ther; 2015 Jul; 151():41-9. PubMed ID: 25749412
[TBL] [Abstract][Full Text] [Related]
3. Use of regulators and inhibitors of Pim-1, a serine/threonine kinase, for tumour therapy (review).
Liang C; Li YY
Mol Med Rep; 2014 Jun; 9(6):2051-60. PubMed ID: 24737044
[TBL] [Abstract][Full Text] [Related]
4. Targeting PIM Kinases to Overcome Therapeutic Resistance in Cancer.
Toth RK; Warfel NA
Mol Cancer Ther; 2021 Jan; 20(1):3-10. PubMed ID: 33303645
[TBL] [Abstract][Full Text] [Related]
5. PIM kinases: From survival factors to regulators of cell motility.
Santio NM; Koskinen PJ
Int J Biochem Cell Biol; 2017 Dec; 93():74-85. PubMed ID: 29108877
[TBL] [Abstract][Full Text] [Related]
6. Mechanism-based combinations with Pim kinase inhibitors in cancer treatments.
Yang Q; Chen LS; Gandhi V
Curr Pharm Des; 2014; 20(42):6670-81. PubMed ID: 25341939
[TBL] [Abstract][Full Text] [Related]
7. Pim kinases in cancer: diagnostic, prognostic and treatment opportunities.
Blanco-Aparicio C; Carnero A
Biochem Pharmacol; 2013 Mar; 85(5):629-643. PubMed ID: 23041228
[TBL] [Abstract][Full Text] [Related]
8. Deletion of Pim kinases elevates the cellular levels of reactive oxygen species and sensitizes to K-Ras-induced cell killing.
Song JH; An N; Chatterjee S; Kistner-Griffin E; Mahajan S; Mehrotra S; Kraft AS
Oncogene; 2015 Jul; 34(28):3728-36. PubMed ID: 25241892
[TBL] [Abstract][Full Text] [Related]
9. Smac mimetic with TNF-α targets Pim-1 isoforms and reactive oxygen species production to abrogate transformation from blebbishields.
Jinesh GG; Laing NM; Kamat AM
Biochem J; 2016 Jan; 473(1):99-107. PubMed ID: 26508734
[TBL] [Abstract][Full Text] [Related]
10. The 44 kDa Pim-1 kinase directly interacts with tyrosine kinase Etk/BMX and protects human prostate cancer cells from apoptosis induced by chemotherapeutic drugs.
Xie Y; Xu K; Dai B; Guo Z; Jiang T; Chen H; Qiu Y
Oncogene; 2006 Jan; 25(1):70-8. PubMed ID: 16186805
[TBL] [Abstract][Full Text] [Related]
11. [The Pim family of protein kinases: structure, functions and roles in hematopoietic malignancies].
Zhukova IuN; Alekseeva MG; Zakharevich NV; Shtil' AA; Danilenko VN
Mol Biol (Mosk); 2011; 45(5):755-64. PubMed ID: 22393773
[TBL] [Abstract][Full Text] [Related]
12. PIM activity in tumours: A key node of therapy resistance.
Rebello RJ; Huglo AV; Furic L
Adv Biol Regul; 2018 Jan; 67():163-169. PubMed ID: 29111105
[TBL] [Abstract][Full Text] [Related]
13. Current perspectives on targeting PIM kinases to overcome mechanisms of drug resistance and immune evasion in cancer.
Malone T; Schäfer L; Simon N; Heavey S; Cuffe S; Finn S; Moore G; Gately K
Pharmacol Ther; 2020 Mar; 207():107454. PubMed ID: 31836451
[TBL] [Abstract][Full Text] [Related]
14. eIF4B is a convergent target and critical effector of oncogenic Pim and PI3K/Akt/mTOR signaling pathways in Abl transformants.
Chen K; Yang J; Li J; Wang X; Chen Y; Huang S; Chen JL
Oncotarget; 2016 Mar; 7(9):10073-89. PubMed ID: 26848623
[TBL] [Abstract][Full Text] [Related]
15. Rational Design of a Potent Pan-Pim Kinases Inhibitor with a Rhodanine-Benzoimidazole Structure.
Sawaguchi Y; Yamazaki R; Nishiyama Y; Sasai T; Mae M; Abe A; Yaegashi T; Nishiyama H; Matsuzaki T
Anticancer Res; 2017 Aug; 37(8):4051-4057. PubMed ID: 28739687
[TBL] [Abstract][Full Text] [Related]
16. PIM kinases: an overview in tumors and recent advances in pancreatic cancer.
Xu J; Zhang T; Wang T; You L; Zhao Y
Future Oncol; 2014 Apr; 10(5):865-76. PubMed ID: 24799066
[TBL] [Abstract][Full Text] [Related]
17. The role of PIM kinases in human and mouse CD4+ T cell activation and inflammatory bowel disease.
Jackson LJ; Pheneger JA; Pheneger TJ; Davis G; Wright AD; Robinson JE; Allen S; Munson MC; Carter LL
Cell Immunol; 2012; 272(2):200-13. PubMed ID: 22078270
[TBL] [Abstract][Full Text] [Related]
18. Targeting Pim kinases for cancer treatment: opportunities and challenges.
Le BT; Kumarasiri M; Adams JR; Yu M; Milne R; Sykes MJ; Wang S
Future Med Chem; 2015; 7(1):35-53. PubMed ID: 25582332
[TBL] [Abstract][Full Text] [Related]
19. eIF4B phosphorylation by pim kinases plays a critical role in cellular transformation by Abl oncogenes.
Yang J; Wang J; Chen K; Guo G; Xi R; Rothman PB; Whitten D; Zhang L; Huang S; Chen JL
Cancer Res; 2013 Aug; 73(15):4898-908. PubMed ID: 23749639
[TBL] [Abstract][Full Text] [Related]
20. The oncogenic PIM kinase family regulates drug resistance through multiple mechanisms.
Isaac M; Siu A; Jongstra J
Drug Resist Updat; 2011; 14(4-5):203-11. PubMed ID: 21601509
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
